GEAP202014945A - Amide-substituted pyridinyltriazole derivatives and uses thereof - Google Patents

Amide-substituted pyridinyltriazole derivatives and uses thereof

Info

Publication number
GEAP202014945A
GEAP202014945A GEAP202014945A GEAP2020014945A GEAP202014945A GE AP202014945 A GEAP202014945 A GE AP202014945A GE AP202014945 A GEAP202014945 A GE AP202014945A GE AP2020014945 A GEAP2020014945 A GE AP2020014945A GE AP202014945 A GEAP202014945 A GE AP202014945A
Authority
GE
Georgia
Prior art keywords
derivatives
pyridinyltriazole
amide
substituted
diseases
Prior art date
Application number
GEAP202014945A
Other languages
English (en)
Inventor
Axel Kretschmer
Carsten Schmeck
Marie-Pierre Collin-Kröpelin
Karoline DRÖBNER
Hanna Tinel
Anja Buchmüller
Klemens Lustig
Chantal Fürstner
Hana Cernecka
Pierre Wasnaire
Elisabeth Pook
Peter Kolkhof
Heiko Schirmer
Thomas Mondritzki
Thomas Neubauer
Matthias Beat Wittwer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of GEAP202014945A publication Critical patent/GEAP202014945A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
GEAP202014945A 2016-05-03 2017-05-02 Amide-substituted pyridinyltriazole derivatives and uses thereof GEAP202014945A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16168165 2016-05-03

Publications (1)

Publication Number Publication Date
GEAP202014945A true GEAP202014945A (en) 2020-05-11

Family

ID=55910850

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP202014945A GEAP202014945A (en) 2016-05-03 2017-05-02 Amide-substituted pyridinyltriazole derivatives and uses thereof
GEAP201714945A GEP20207158B (en) 2016-05-03 2017-05-02 Amide-substituted pyridinyltriazole derivatives and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP201714945A GEP20207158B (en) 2016-05-03 2017-05-02 Amide-substituted pyridinyltriazole derivatives and uses thereof

Country Status (42)

Country Link
US (4) US9988367B2 (OSRAM)
EP (1) EP3452463B1 (OSRAM)
JP (1) JP6932140B2 (OSRAM)
KR (1) KR20190003655A (OSRAM)
CN (2) CN109415347B (OSRAM)
AR (1) AR108262A1 (OSRAM)
AU (1) AU2017259870B2 (OSRAM)
BR (1) BR112018072542A2 (OSRAM)
CA (1) CA3022749A1 (OSRAM)
CL (1) CL2018003105A1 (OSRAM)
CO (1) CO2018011933A2 (OSRAM)
CR (1) CR20180522A (OSRAM)
CU (1) CU24567B1 (OSRAM)
CY (1) CY1124084T1 (OSRAM)
DK (1) DK3452463T3 (OSRAM)
DO (1) DOP2018000240A (OSRAM)
EA (1) EA035596B1 (OSRAM)
EC (1) ECSP18081881A (OSRAM)
ES (1) ES2866109T3 (OSRAM)
GE (2) GEAP202014945A (OSRAM)
HR (1) HRP20210648T1 (OSRAM)
HU (1) HUE053908T2 (OSRAM)
IL (1) IL262557B (OSRAM)
JO (1) JOP20170105B1 (OSRAM)
LT (1) LT3452463T (OSRAM)
MA (1) MA44851B1 (OSRAM)
MX (1) MX381787B (OSRAM)
NI (1) NI201800115A (OSRAM)
PE (1) PE20190116A1 (OSRAM)
PH (1) PH12018502268A1 (OSRAM)
PL (1) PL3452463T3 (OSRAM)
PT (1) PT3452463T (OSRAM)
RS (1) RS61771B1 (OSRAM)
SG (1) SG11201809752VA (OSRAM)
SI (1) SI3452463T1 (OSRAM)
SV (1) SV2018005771A (OSRAM)
TN (1) TN2018000368A1 (OSRAM)
TW (1) TWI772295B (OSRAM)
UA (1) UA123791C2 (OSRAM)
UY (1) UY37220A (OSRAM)
WO (1) WO2017191102A1 (OSRAM)
ZA (1) ZA201808131B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6911052B2 (ja) * 2016-05-03 2021-07-28 バイエル ファーマ アクチエンゲゼルシャフト オキソアルキル置換フェニルトリアゾール誘導体およびその使用
US10703742B2 (en) * 2016-05-03 2020-07-07 Bayer Pharma Aktiengesellschaft Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4-triazole derivatives
PE20190913A1 (es) 2016-05-03 2019-06-26 Bayer Pharma AG Derivados aromaticos de sulfonamida
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
US10893352B2 (en) * 2016-08-24 2021-01-12 Matthew Hawkes Programmable interactive stereo headphones with tap functionality and network connectivity
US10954197B2 (en) * 2017-03-08 2021-03-23 Yogee's Bioinnovations Private Limited Cathepsin-D and angiogenesis inhibitors and compositions thereof for treating breast cancer
CA3072427C (en) 2017-08-08 2023-12-05 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
EP3700896A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
US20210253557A1 (en) 2017-10-24 2021-08-19 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
EP3700913B1 (en) 2017-10-24 2021-11-10 Bayer Aktiengesellschaft Prodrugs of substituted triazole derivatives and uses thereof
EP3700900A1 (en) 2017-10-24 2020-09-02 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
EP3700899A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CA3084421A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
US11020351B2 (en) * 2018-03-26 2021-06-01 Hetero Labs Limited Stable bilayer tablet compositions
WO2019199273A1 (en) * 2018-04-10 2019-10-17 Hewlett-Packard Development Company, L.P. Preheat dyed build materials with preheating sources
JP7279200B2 (ja) * 2019-12-24 2023-05-22 東京エレクトロン株式会社 成膜方法及び成膜システム
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
WO2024118667A1 (en) * 2022-11-29 2024-06-06 The United States Government As Represented By The Department Of Veterans Affairs Eif4a1 inhibitors with antitumor activity

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042466A1 (de) 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5468448A (en) 1989-12-28 1995-11-21 Ciba-Geigy Corporation Peroxide disinfection method and devices therefor
DE4107857A1 (de) 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP3290657B2 (ja) 1991-05-01 2002-06-10 メルク エンド カムパニー インコーポレーテッド アンギオテンシンii拮抗剤として活性な酸性アラルキルトリアゾール誘導体
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6844005B2 (en) 2002-02-25 2005-01-18 Trutek Corp Electrostatically charged nasal application product with increased strength
FR2708608B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
ATE298338T1 (de) 1997-12-17 2005-07-15 Merck & Co Inc Integrin-rezeptor-antagonisten
DE19816882A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
ATE288900T1 (de) 1998-07-24 2005-02-15 Bayer Cropscience Ag Substituierte benzoylcyclohexandione
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
EA004656B1 (ru) 1999-04-01 2004-06-24 Пфайзер Продактс Инк. Аминопиримидины в качестве ингибиторов сорбитолдегидрогеназы
DE19920791A1 (de) 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19929348A1 (de) 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US6531142B1 (en) 1999-08-18 2003-03-11 The Procter & Gamble Company Stable, electrostatically sprayable topical compositions
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR027575A1 (es) 2000-03-06 2003-04-02 Bayer Ag Benzoilciclohexenonas substituidas
US7080644B2 (en) 2000-06-28 2006-07-25 Microdose Technologies, Inc. Packaging and delivery of pharmaceuticals and drugs
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP4673295B2 (ja) 2003-03-14 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロヒダントインcgrp受容体拮抗物質
CA2571907A1 (en) 2003-06-27 2005-01-27 Berglin Corporation Of Washington Machine for precision low stress coring and slicing of apples and other soft-cored or pitted fruits
AU2004309164B2 (en) 2003-12-22 2007-11-15 Pfizer Inc. Triazole derivatives as vasopressin antagonists
EP1722788A4 (en) 2004-03-08 2008-02-13 Wyeth Corp MODULATORS OF IONIC CHANNELS
JP2007527909A (ja) 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
US20070225333A1 (en) 2004-04-28 2007-09-27 Bryans Justin S 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2006117657A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102009013642A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
AU2011219746B2 (en) * 2010-02-27 2015-04-23 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2682394A1 (de) 2010-07-09 2014-01-08 Bayer Intellectual Property GmbH 1H-Pyrazolo[3,4-b]pyridin-Triazine Verbindungen und ihre Verwendung zur Behandlung bzw. Prophylaxe von Herz-Kreislauf-Erkrankungen
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
EP2623499B1 (en) * 2010-10-01 2015-04-22 Taisho Pharmaceutical Co., Ltd 1,2,4-triazolone derivative
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US8906902B2 (en) 2012-03-22 2014-12-09 Biota Europe Limited Antibacterial compounds
MA40893B1 (fr) 2014-11-03 2018-11-30 Bayer Pharma AG Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
US10703742B2 (en) * 2016-05-03 2020-07-07 Bayer Pharma Aktiengesellschaft Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4-triazole derivatives
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
JP6911052B2 (ja) * 2016-05-03 2021-07-28 バイエル ファーマ アクチエンゲゼルシャフト オキソアルキル置換フェニルトリアゾール誘導体およびその使用

Also Published As

Publication number Publication date
US11091463B2 (en) 2021-08-17
CN113121504A (zh) 2021-07-16
CR20180522A (es) 2019-01-15
CU24567B1 (es) 2022-01-13
US20200017473A1 (en) 2020-01-16
TW201806941A (zh) 2018-03-01
DOP2018000240A (es) 2019-03-15
EP3452463B1 (en) 2021-03-24
JOP20170105B1 (ar) 2022-03-14
ZA201808131B (en) 2021-05-26
CL2018003105A1 (es) 2019-02-15
CY1124084T1 (el) 2022-05-27
US20190144423A1 (en) 2019-05-16
DK3452463T3 (da) 2021-04-26
SV2018005771A (es) 2019-01-04
EA035596B1 (ru) 2020-07-14
MA44851A (fr) 2019-03-13
GEP20207158B (en) 2020-10-12
US20180251447A1 (en) 2018-09-06
UY37220A (es) 2017-11-30
HRP20210648T1 (hr) 2021-05-28
ECSP18081881A (es) 2018-11-30
CN109415347B (zh) 2021-05-07
MA44851B1 (fr) 2021-09-30
CN109415347A (zh) 2019-03-01
CU20180134A7 (es) 2019-06-04
NI201800115A (es) 2019-03-14
AU2017259870A1 (en) 2018-11-15
US9988367B2 (en) 2018-06-05
PE20190116A1 (es) 2019-01-16
RS61771B1 (sr) 2021-05-31
TN2018000368A1 (en) 2020-06-15
US20170320854A1 (en) 2017-11-09
IL262557B (en) 2022-01-01
EP3452463A1 (en) 2019-03-13
MX381787B (es) 2025-03-13
PL3452463T3 (pl) 2021-08-09
UA123791C2 (uk) 2021-06-02
SG11201809752VA (en) 2018-12-28
SI3452463T1 (sl) 2021-07-30
PH12018502268A1 (en) 2019-07-15
JP6932140B2 (ja) 2021-09-08
EA201892505A1 (ru) 2019-04-30
BR112018072542A2 (pt) 2019-03-26
TWI772295B (zh) 2022-08-01
WO2017191102A1 (en) 2017-11-09
KR20190003655A (ko) 2019-01-09
MX2018013335A (es) 2019-05-09
LT3452463T (lt) 2021-04-26
HUE053908T2 (hu) 2021-07-28
ES2866109T3 (es) 2021-10-19
PT3452463T (pt) 2021-04-28
JP2019514945A (ja) 2019-06-06
IL262557A (en) 2018-12-31
AU2017259870B2 (en) 2021-07-15
CA3022749A1 (en) 2017-11-09
CO2018011933A2 (es) 2018-11-22
AR108262A1 (es) 2018-08-01
US10472348B2 (en) 2019-11-12

Similar Documents

Publication Publication Date Title
GEAP202014945A (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
PH12017500802A1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
MX2021015106A (es) Inhibidores de ferroportina novedosos.
EP4302834A3 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
PH12015502792A1 (en) Crystalline bromodomain inhibitors
GEAP201914680A (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12018501084B1 (en) Heterocyclic compounds as immunomodulators
GEAP201914679A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MY189453A (en) 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
MX2017010277A (es) Cenicriviroc para el tratamiento de la fibrosis.
PH12019500808A1 (en) Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof
MX2019008603A (es) Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer.
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.